Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, et al. BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220–6. Beran J, Šalapová E, Špajdel M. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016;16(1):648. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. https://doi.org/10.1101/2020.04.16.20065920.

Yamasmith E, Avirutnan P, Mairiang D, Tanrumluk S, Suputtamongkol Y, Saleh-arong FA, et al. Efficacy and Safety of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind, Placebo-controlled Trial. ClinicalTrials.gov Identifier: NCT02045069. 2015. Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nat Med. 2013;19(10):1313–7. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. Studie tolerance u zdravých jedinců a pacientů důsledně prokázaly, že inosin pranobex nemá závažné vedlejší účinky. Kontinuální podávání léčiva po dobu až 7 let, v dávkách v rozmezí od 1 do 8 g denně, jen občas způsobilo přechodnou nevolnost. Tato nevolnost byla spojena s velkým počtem požitých tablet. Kromě toho bylo hlášeno přechodné zvýšení hladiny kyseliny močové v séru a moči. Toto zvýšení koncentrace kyseliny močové v séru je častější u mužských pacientů než u žen. [3] Užití proti SARS-CoV-2 [ editovat | editovat zdroj ] Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005;19(1):111–22.

Warnings

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;12:105938. Shen L, Yang Y, Ye F, Liu G, Desforges M, Talbot PJ, et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother. 2016;60(9):5492–503.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.Vírusové ochorenia s dlhším vývojom: v liečbe treba pokračovať ešte 1-2 týždne po ústupe symptómov, prípadne dlhšie, podľa rozhodnutia lekára. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969;4(2):203–14.

zāles ir parakstītas tikai Jums. Nedodiet tās citiem. Tās var nodarīt ļaunumu pat tad, ja šiem cilvēkiem ir līdzīgas slimības pazīmes. Jung E, Nam S, Oh H, Jun S, Ro H-J, Kim B, et al. Neutralization of acidic intracellular vesicles by Niclosamide inhibits multiple steps of the dengue virus life cycle in vitro. Sci Rep. 2019;9(1):8682. a b BARTŮŇKOVÁ, Jiřina. Imunodeficience. 2., přeprac. a dopl. vyd. vyd. Praha: Grada 254 s., [4] s. barev. obr. příl.s. Dostupné online. ISBN 978-80-247-1980-1, ISBN 80-247-1980-0. OCLC 124088004 Treatment of genital warts in combination with other treatments such as podophyllin or carbon dioxide laser. Izquierdo L, Helle F, François C, Castelain S, Duverlie G, Brochot E. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenomics Pers Med. 2014;7:241–9.de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RWAL, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin a or interferon-α treatment. J Gen Virol. 2013;94(8):1749–60. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020. SLIVA, Jiri; PANTZARTZI, Chrysoula N.; VOTAVA, Martin. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Advances in Therapy. 08 2019, roč. 36, čís. 8, s. 1878–1905. PMID 31168764 Que TL, Wong VC, Yuen KY. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399–406. CQ has some activity in mice against human coronavirus OC43 [ 60]. Both CQ and HCQ reach up to 700 times higher level in lungs than in plasma [ 50]. According to pharmacology based pharmacokinetic modelling by Yao et al., simulated lung, blood and plasma concentration of CQ increased slowly after the first dose was given and was yet to achieve steady-state on Day 10. However, in HCQ, the concentration increased rapidly and reached a steady-state following the initial loading dose and subsequent maintenance dose [ 58].